LCM
HRMY icon

Legato Capital Management’s Harmony Biosciences HRMY Stock Holding History

Legato Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,391
Closed -$988K – 805
2025
Q4 		$988K Sell
26,391
-25,024
-49% -$823K 0.09% 361
2025
Q3 		$1.42M Buy
51,415
+19,504
+61% +$672K 0.15% 205
2025
Q2 		$1.01M Hold
31,911
– – 0.12% 275
2025
Q1 		$1.06M Buy
31,911
+5,191
+19% +$186K 0.14% 233
2024
Q4 		$919K Buy
26,720
+5,506
+26% +$189K 0.12% 315
2024
Q3 		$849K Buy
+21,214
New +$745K 0.1% 349
2023
Q3 		– Sell
-5,870
Closed -$207K – 583
2023
Q2 		$207K Buy
+5,870
New +$203K 0.03% 517

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Legato Capital Management's HRMY Position: Q1 2026 in Review

Legato Capital Management sold out of Harmony Biosciences (HRMY) in Q1 2026, closing a stake of 26,391 shares — an estimated $988K sold.

Legato Capital Management first reported a position in HRMY in Q2 2023 and held it in 7 quarters. The position peaked at $1.42M in Q3 2025. 309 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • Legato Capital Management reported no remaining Harmony Biosciences position as of Q1 2026 after selling out during the quarter.
  • Legato Capital Management sold 26,391 Harmony Biosciences shares in Q1 2026, an estimated $988K.
  • Legato Capital Management first reported a position in Harmony Biosciences in Q2 2023 and held it in 7 quarters.
  • Legato Capital Management's Harmony Biosciences position peaked at $1.42M in Q3 2025.
  • 309 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.